Allergan bid opens new battlefront for activist funds

The bid by Bill Ackman's Pershing Square and Valeant Pharmaceuticals for Allergan is a seminal moment in M&A and could pave the way for more corporate players to team up with an activist shareholder.

Bill Ackman’s Pershing Square Capital Management has opened a brave new world for activist funds with its move to team up with Valeant Pharmaceuticals to make a hostile takeover offer for botox maker Allergan, say investment bankers and lawyers.

Chris Young, who heads Credit Suisse’s global contested situations team in New York that deals with activist funds, says this pairing to try and acquire a company is a watershed development.

{{content.question}}

Mastercard

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to proceed…

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access

Mastercard

Updating information

Please wait ...

  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership

Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles